Navigation Links
In muscular dystrophy, what matters to patients and doctors can differ
Date:7/25/2012

Complex, multi-system diseases like myotonic dystrophy the most common adult form of muscular dystrophy require physicians and patients to identify which symptoms impact quality of life and, consequently, what treatments should take priority. However, a new study out this month in the journal Neurology reveals that there is often a disconnect between the two groups over which symptoms are more important, a phenomenon that not only impacts care but also the direction of research into new therapies.

"In order to design better therapies we must first develop a clear understanding of what patients think are the key mental and physical burdens of this disease," said University of Rochester Medical Center (URMC) neurologist Chad Heatwole, M.D., lead author of the study. "It is clear from this study that, in the case of myotonic dystrophy, researchers have not always been concentrating on the symptoms that are most important to the patient."

Myotonic dystrophy has been characterized as one of the most diverse and complex genetic diseases with a wide range of symptoms ranging from fatigue, muscle weakness, cognitive impairment, depression, difficulty sleeping, impaired vision, pain, difficulty swallowing, gastrointestinal problems, and myotonia, the inability to relax muscles after contraction such as when clenching a fist that is the hallmark of the disease. The severity and onset of these symptoms can vary from patient to patient.

As a result, physicians and patients are often confronted with a bewildering array of treatment options and researchers have previously had no comprehensive method to measure the meaningful impact of experimental therapies. Further impetus for a patient-centered approach has come from a recent push by the federal Food and Drug Administration to require that new drugs take into account what outcomes patients feel are important.

Using a national database of muscular dystrophy patients developed by URMC, Heatwole and his colleagues surveyed 278 people with myotonic dystrophy type-1. They asked them not only which symptoms they were experiencing, but which ones have the most impact on their lives. Answers were cross referenced with the respondent's age and a genetic measure called CTG repeat length that roughly correlates with the severity of the disease.

The study revealed that certain symptoms like myotonia which are experienced by more than 90 percent of individuals with the disease are less important to patients than symptoms such as such as fatigue, limited mobility, and sleep problems. Respondents also identified specific symptoms that have the greatest impact on their lives. These included difficulty having children, not being able to stay in the standing position, and difficulty holding down a job.

"One of the more surprising results is that myotonia the condition that gives the disease its name is down the list of things that patients feel most affect their daily lives," said Heatwole. "These insights will not only have important implications for how patients are treated, but also how new therapies for the disease are evaluated by building better outcome measures."

Using this data, Heatwole and his colleagues have developed a questionnaire for myotonic dystrophy patients that weights patient responses based on their study findings. The questionnaire, called a disease-specific patient reported outcome measure is one of many which is being developed for neuromuscular diseases at the URMC by Heatwole and his team and will enable researchers to more precisely measure whether the impact of experimental therapies is meaningful to patients. The myotonic dystrophy outcome measure is already being used in two clinical trials at the University of Rochester.


'/>"/>
Contact: Mark Michaud
mark_michaud@urmc.rochester.edu
585-273-4790
University of Rochester Medical Center
Source:Eurekalert

Related medicine news :

1. Leading experts on congenital muscular dystrophy convene at University of Nevada, Reno
2. Cedars-Sinai researchers, with stem cells, advance understanding of spinal muscular atrophy
3. University of Nevada School of Medicine researcher reviews muscular dystrophy therapies
4. Clinical trial first to test heart drug regimen for Duchenne muscular dystrophy
5. Jeffrey W. Olin, DO, authors study that describes symptoms and severity of fibromuscular dysplasia
6. Muscular Development Store Releases the Optimum Performance Workout for High Intensity Training
7. New gene transfer strategy shows promise for limb girdle and other muscular dystrophies
8. Mesothelioma Victims Center Now Offers A US Navy Veteran Individual Or Family Dealing With Mesothelioma The Names Of The Best Mesothelioma Attorneys--Quality Matters
9. Mesothelioma Victims Center Urges US Navy Veterans or Anyone with Mesothelioma to Call Them for the Names of the Best Mesothelioma Attorneys in the US-Quality Matters
10. Higher-spending hospitals have fewer deaths for emergency patients
11. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... January 16, 2017 , ... Etymotic Research, ... GunSport•PRO® and EB15•LE® electronic earplugs at the NSSF SHOT Show on January 17-20, ... The SHOT Show is the shooting, hunting and outdoor trade show and conference ...
(Date:1/16/2017)... ... 16, 2017 , ... As New York’s fastest growing ophthalmic ... to their medical staff, according to eye surgeon, Jeffrey Martin, MD, FACS, Chief ... division of SightMD. Dr. Giamos will practice primarily out of SightMD’s Riverhead, Southampton, ...
(Date:1/16/2017)... ... ... are well-aware of the following facts at present:, Flu and ... no effect on keeping this particularly bad strain of the flu away , ... sniffling , These facts are well-known among the team at Woodard! About ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... One thing ... only to treat, but to test for, as well. The money spent screening for ... year.(1) Doctors in the U.S. screen patients for cancer more than in any other ...
(Date:1/15/2017)... ... , ... In this role, Courtney will be responsible for developing new business ... friendly mark. This certification program was created by ASL and the nonprofit Asthma and ... suitable for the 60+ million people living in the U.S. with asthma and allergies. ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , January 17, 2017 ... to potentially earn millions in revenue with the planned ... massive numbers of strokes with a simple test that ... Companies with latest developments in the markets today include: ... (NYSE: AZN ), Cancer Genetics, Inc. (NASDAQ: ...
(Date:1/17/2017)... 17, 2017 Catherine ... http://www.touchneurology.com/articles/tailored-temperature-management-neurocritical-care ...      (Logo: ... European Neurological Review , ... Amey reports that despite standard care, temperatures ...
(Date:1/17/2017)... 17, 2017  The pioneer in no-touch UV disinfection has ... Tru-D SmartUVC , short for "total room ultraviolet disinfection," was ... Terminal Room-Disinfection (BETR-D) study which was recently published in ... that Tru-D can cut transmission of four major superbugs by ... to market in 2007, we have been committed to innovation ...
Breaking Medicine Technology: